R&D News | pharmaphorum

News

AZ's Alexion inks wide-ranging AI agreement with Verge

AstraZeneca has made a sizeable play in applying artificial intelligence to drug discovery in its rare disease unit Alexion, partnering with Verge Genomics in a deal that

News

WCLC: Data back first-line use of Gilead, AZ/Daiichi TROP2s

AstraZeneca/Daiichi Sankyo and Gilead Sciences have reported preliminary results of studies that suggest their TROP2-targeted antibody-drug conjugates (ADCs) could have a

News

WCLC: Daiichi Sankyo HER3 ADC readout sets up filings

A mid-stage trial of Daiichi Sankyo's HER3-targeting antibody-drug conjugate patritumab deruxtecan has hit the mark and will form the basis of regulatory filings for the d

News

Apollo, Nimbus lead bumper week for biotech financings

This week saw a series of big-ticket funding rounds for biotech companies, with Apollo Therapeutics and Nimbus Therapeutics both pulling in upwards of $200 million, in a p

News

Seagen partners Nurix on 'degrader-antibody conjugates'

Seagen hasn't let a pending acquisition by Pfizer interrupt its business development activities, adding to its pipeline with a wide-ranging partnership with Nurix Therapeu

News

Lift for Roche as Alnylam drug lowers blood pressure

Just weeks after wagering $310 million upfront on the rights to Alnylam's hypertension therapy zilebesiran on the strength of phase 1 data, Roche has been rewarded by a po

AZ's Alexion inks wide-ranging AI agreement with Verge

WCLC: Data back first-line use of Gilead, AZ/Daiichi TROP2s

WCLC: Daiichi Sankyo HER3 ADC readout sets up filings

Apollo, Nimbus lead bumper week for biotech financings

Seagen partners Nurix on 'degrader-antibody conjugates'

Lift for Roche as Alnylam drug lowers blood pressure

Pharvaris plans filings for HAE drug after pivotal trial win

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks